## **REMARKS**

Claims 1-10 are active in the present application. Claims 4-9 have been amended to remove multiple dependencies. No new matter is added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record Registration No. 24,618

Daniel J. Pereira, Ph.D. Registration No. 45,518

22850

(703) 413-3000 Fax #: (703)413-2220 NFO/DJPER/SUKOS/js

I:\atty\SUKOS\June\208858US-PR.wpd

208858US-0 PCT

Marked-Up Copy
Serial No: 09 831, 888
Amendment Filed on: 01-19-01

## IN THE CLAIMS

- --4. (Amended) Pressurized metered dose inhalers according to [any of claims from 1 to 3] claim 1, containing a low-volatility component selected from glycerol, polyethylene glycol and isopropyl myristate.
- 5. (Amended) Pressurized metered dose inhalers according to [any of claims from 1 to 4] claim 1, wherein the co-solvent is ethanol.
- 6. (Amended) Pressurized metered dose inhalers according to [any of claims from 1 to 5] claim 1, wherein the propellant is selected from HFA 227, HFA 134a and their mixtures.
- 7. (Amended) Pressurised metered dose inhalers according to [any of claims 1 to 6] claim 1, wherein part or all of the internal surfaces are coated with an epoxy phenol resin.
- 8. (Amended) Pressurised metered dose inhalers according to [any of claims 1 to 5] claim 1, wherein part or all of the internal surfaces consist of anodised aluminium.
- 9. (Amended) Stabilized aerosol solution formulation consisting of an active ingredient in a hydrofluorocarbon propellant, a co-solvent and optionally a low-volatility component for use in a pressurised metered dose inhaler as claimed in [any of claims 1 to 8] claim 1.--